US Oncology Research Affiliated Investigators Participated in Studies that will be Presented at the 2011 American Society of Hematology Annual Meeting and Exposition
Fifteen leading investigators affiliated with US Oncology Research involved in two oral clinical studies presentations and ten posters
THE WOODLANDS, Texas, Nov. 29, 2011 /PRNewswire/ -- Fifteen leading investigators affiliated with US Oncology Research participated in studies that will be presented and displayed at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. ASH will take place Dec. 10-13 and is an educational and scientific program that helps Hematology professionals stay up-to-date on the latest research, therapies, and tools needed to be successful in their field.
(Logo: http://photos.prnewswire.com/prnh/20110912/DA65711LOGO)
Jeff Sharman, M.D., medical oncologist with Willamette Valley Cancer Institute and Research Center – Riverbend, participated in a study that will be presented Dec. 13 at 8:30 am PST in an oral presentation. The study titled "The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study," shows that PCI-32765 is a very well tolerated once daily pill with significant activity in CLL and Mantle Cell lymphoma.
"When we presented our data with the Syk inhibitor fostamatinib at the ASH plenary session in 2008, B Cell Receptor signaling inhibitors were heralded as a breakthrough on par with the original use of chlorambucil, adriamycin, and rituximab," said Dr. Sharman. "At the time, the assertion seemed excessively optimistic. Now with mature data on agents such as PCI-32765, CAL-101, and AVL-292, which each target proteins in the BCR signaling pathway, I have become a believer."
Dr. Sharman is involved in five separate presentations involving lymphoid malignancies and is first author in two. "Our US Oncology Research group has been able to take a leadership position in drug development for CLL / NHL," added Dr. Sharman. "It is very exciting to be as involved with these projects as we are."
Roger Lyons, M.D., F.A.C.P., president and hematologist with Cancer Care Centers of South Texas, participated in another study that will also be presented orally Dec. 12 at 7:15 am PST titled "Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I." The study conducted was a randomized, placebo-controlled study of 309 Myelofibrosis patients to establish the effects of ruxolitinib or a placebo. This drug was approved by the FDA on Nov. 16 based on this data and a previous phase 2 study. Unlike many other drug developments, approval was achieved in less than five years from initiation of the first in human trials.
"During the oral presentation, the effects of this new drug will be revealed to show whether Myelofibrosis patients will now have a therapy targeting their specific cancer, which they've never had before," said Dr. Lyons. "It is an exciting discovery."
Drs. Lyons and Sharman, along with several other US Oncology Research affiliated investigators, were involved in ten other abstracts that will be displayed as posters at the conference.
|
|
5:30-7:30 pm PST, Saturday, Dec. 10: A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Jeff Sharman, MD(1)*, Sven de Vos, MD, PhD(2)*, John P. Leonard, MD(3), Richard R. Furman, MD(4), Steven E. Coutre, MD(5), Ian W. Flinn, MD, PhD(6), Marshall T. Schreeder(7)*, Jaqueline C. Barrientos, MD(8), Nina D. Wagner-Johnston(9), Thomas Boyd, MD(10)*, Nathan H. Fowler, MD(11), Leanne Holes(12)*, Brian Lannutti(12), David Johnson(12)*, Thomas M. Jahn(12)* and Langdon L Miller(12)* |
|
|
|
|
|
5:30-7:30 pm PST, Saturday, Dec. 10: Variation in Health-Related Quality of Life by Age among Patients with Chronic Lymhocytic Leukemia Chris L. Pashos, PhD(1)*, Christopher R Flowers, MD(2), Mark Weiss, MD(3)*, Nicole Lamanna, MD(4), Charles M Farber, MD, PhD(5)*, Thomas J. Kipps, M.D., Ph.D(6), Susan Lerner, MS, BA(7)*, Neil Kay, MD(8), Jeff Porte Sharman, MD(9), David L. Grinblatt, MD(10)*, Ian W. Flinn, MD, PhD(11), Mark Kozloff, MD(12)*, Arlene S Swern, PhD(13)*, Zeba M. Kahn, Ph.D(13)*, Thomas K. Street, RPh(13)*, Kristen A Sullivan, MBA(14)*, Gale Harding, MA(15)* and Michael J Keating, MD(16) |
|
|
|
|
|
6:00-8:00 pm PST, Sunday, Dec. 11: 24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients Roger M. Lyons, MD(1,2), Billie J. Marek(1,3)*, Surabhi Sharma(4)*, Carole Paley(4)*, Jason Esposito(4)*, Lawrence Garbo, MD(1,5), Nicholas DiBella(1,6)* and Guillermo Garcia-Manero(7) |
|
|
|
|
|
6:00-8:00 pm PST, Sunday, Dec. 11: Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Azra Raza, MD(1), Naomi Galili, Ph.D.(2)*, Deborah Mulford, MD(3), Scott E. Smith, MD, PhD, FACP(4)*, Gail Brown, MD(5), Lisa Meng, PhD(5)*, David P. Steensma, MD(6), Roger M. Lyons, MD(7,8), Ralph Boccia, MD(9)*, Mikkael A. Sekeres, MD, MS(10), Guillermo Garcia-Manero(11) and Ruben A. Mesa, MD(12) |
|
|
|
|
|
6:00-8:00 pm PST, Sunday, Dec. 11: Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect CLL Disease Registry Jeff Sharman, MD(1)*, Christopher R Flowers, MD(2)*, Mark Weiss, MD(3)*, David Grinblatt, MD(4)*, Charles Farber, MD, PhD(5)*, Neil Kay, MD(6), Thomas Kipps, MD(7)*, Nicole Lamanna, MD(8)*, Chris Pashos, PhD(9)*, Ian W Flinn, MD(10)*, Mark Kozloff, MD(11)*, Susan Lerner, MS(12)*, Arlene S Swern, PhD(13)*, Kristen A Sullivan, MBA(14)*, Thomas K. Street, RPh(13)* and Michael Keating, MBBS(12)* |
|
|
|
|
|
6 :00-8 :00 pm PST, Sunday, Dec. 11: A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal 101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL) |
|
|
|
|
|
6 :00-8 :00 pm PST, Sunday, Dec. 11: Update of an Open-Label Extension Study Evaluating the Long-Term Safety & Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS) Pierre Fenaux, MD, PhD(1), Hagop M. Kantarjian(2), Petra Muus, MD, PhD(3), Roger M. Lyons, MD(4), Richard A. Larson, MD(5), Mikkael A. Sekeres, MD, MS(6), Pamela S. Becker, MD, PhD(7), Catherine Jia, PhD(8)* and Allen S. Yang, MD, PhD(9) |
|
|
|
|
|
6 :00-8 :00 pm PST, Sunday, Dec. 11: A Critical Population Analysis of 57,500 US Multiple Myeloma Patients: Impact of Race, Age, and Decade of Treatment on Overall Survival Hakan Kaya, MD(1), Danko Martincic, MD(2), Irfan Jawed, MD(1)*, Ben Peressini, MS(1)*, Ameer L Elaimy(1)* and Christopher M Lee, MD(1)* |
|
|
|
|
|
6:00-8:00 pm PST, Monday, Dec. 12: Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients >70 Years of Age with Chronic Lymphocytic Leukemia Receiving Bendamustine with or without Rituximab Kathryn S. Kolibaba, MD(1,2), Avani D. Joshi, BPharm, PhD(2)*, James A. Sterchele, PharmD(3), Michael Forsyth, RPh, MBA(2)*, Erin Alwon, MS(2)*, Hooman Beygi, PhD(3)* and Gerard T. Kennealey, MD(3) |
|
|
|
|
|
6:00-8:00 pm PST, Monday, Dec. 12: Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP) Jeffrey Wasser, MD(1), Ralph Vincent V. Boccia, MD(2), Roger M. Lyons, MD(3), Romeo Mandanas(4)*, Ingrid Pabinger(5), Marc Michel IV(6)*, Jean-Francois Viallard, MD-PhD(7)*, Xuena Wang, PhD(8)* and Richard Lizambri, MD(8)* |
|
|
In addition to the above abstracts being presented at the conference, they were also published in print and online in the November 18 supplemental volume of Blood.
Many clinical studies led by US Oncology Research affiliated physicians were also prominently featured at numerous conferences held around the world, including the annual congress for the European Society for Medical Oncology (ESMO), the annual meeting for the American Society for Clinical Oncology (ASCO) and the San Antonio Breast Cancer Symposium (SABCS). Those studies, along with more than 72 published investigator-initiated manuscripts, featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow. For a complete list, please contact US Oncology Research at 281-863-1000.
About US Oncology Research
McKesson Specialty Health conducts clinical trials through US Oncology Research, which draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in over 250 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 50,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.
About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckessonspecialtyhealth.com.
1. Names that are bold are affiliated with US Oncology Research
SOURCE McKesson Specialty Health
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article